Bezuclastinib and Sunitinib for Gastrointestinal Stromal Tumors

Bezuclastinib and Sunitinib for Gastrointestinal Stromal Tumors
100%75%50%25%0%May 21May 22May 23May 24May 25May 21 • YES 40.1%May 22 • YES 41.2%May 23 • YES 42.1%May 24 • YES 29.4%May 25 • YES 29.9%
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for Advanced Gastrointestinal Stromal Tumor

Advanced Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumor is a rare cancer that starts in the wall of the digestive tract. In advanced disease, delaying tumor growth can mean more time before cancer causes new problems.

1U.S. diagnoses: About 6,000 per year2Common tumor sites: 60% stomach, 35% small intestine3Distant-stage survival: 57% at 5 years